LRP1B and prostate carcinoma: Zhang L. et al. and Zhang Z. et al. found, in gastric and prostate cancer, respectively, that miR-500 functions as an oncomir, which promotes, in both cases, cancer cell proliferation, survival and tumorigenicity through the activation of the NF-kB-signaling pathway [118,119] or through the inhibition of LRP1B.